Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin

Journal of Gene Medicine

Volumn 7, Issue 8, 2005, Pages 1044-1052

  Ito, Makoto ^a   Yamamoto, Seiji ^a   Nimura, Keisuke ^a   Hiraoka, Kazuya ^a   Tamai, Katsuto ^a   Kaneda, Yasufumi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer therapy; Chemotherapy; Drug delivery; Non viral vector; Rad51; siRNA

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANNEXIN; CISPLATIN; RAD51 PROTEIN; SMALL INTERFERING RNA; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL COUNT; CONTROLLED STUDY; DRUG SENSITIVITY; FIBROBLAST; FLUORESCENCE ACTIVATED CELL SORTING; GENE TRANSFER; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SENDAI VIRUS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL COUNT; CELL LINE, TUMOR; CHICK EMBRYO; CISPLATIN; FIBROBLASTS; GENETIC VECTORS; HELA CELLS; HUMANS; MALE; MICE; MICE, SCID; RAD51 RECOMBINASE; RNA, MESSENGER; RNA, SMALL INTERFERING; SENDAI VIRUS; TUMOR BURDEN;

SENDAI VIRUS;

EID: 23344453535     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.753     Document Type: Article

References (43)

1. Baird RD, Kaye SB. Drug resistance reversal - are we getting closer? Eur J Cancer 2003; 39: 2450-2461.
2. Links M, Brown R. Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Expert Rev Mol Med 1999; Oct 25: 1-21.
3. Fojo T, Bates S. Strategies for reversing drug resistance. Oncogene 1988; 22: 7512-7523.
4. Holleran WM, DeGregorio MW. Evolution of high-dose cisplatin. Invest New Drugs 1988; 6: 135-142.
5. Weiss RB, Christian MC. New cisplatin analogues in development. Drugs 1993; 46: 360-377.
6. Silvani A, Eoli M, Salmaggi A, et al. Phase II trial of cisplatin plus temozolomide in recurrent and progressive malignant glioma patients. J Neurooncol 2003; 66: 203-208.
7. Roberts JJ, Kotsaki-Kovatsi VP. Potentiation of sulphur mustard or cisplatin-induced toxicity by caffeine in Chinese hamster cells correlates with formation of DNA double-strand breaks during replication on a damaged template. Mutat Res 1986; 165: 207-220.
8. Kanno S, Hyodo M, Suzuki K, Ohkido M. Effect of DNA-damaging agents on DNA replication and cell-cycle progression of cultured mouse mammary carcinoma cells. Jpn J Cancer Res 1985; 76: 289-296.
9. Zdraveski ZZ, Mello JA, Marinus MG, Essigmann JM. Multiple pathways of recombination define cellular responses to cisplatin. Chem Biol 2000; 7: 39-50.
10. Xu Z, Chen ZP, Malapesta A, et al. DNA repair protein level vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anticancer Drugs 2002; 13: 511-519.
11. D'Andrea AD, Grompe M. The Fanconi anemia/BRCA pathway. Nat Rev Cancer 2003; 3: 23-34.
12. Sherr CJ. Principles of tumor suppression. Cell 2004; 116: 235-246.
13. Henning W, Sturzbecher H-W. Homologous recombination and cell cycle checkpoints: Rad51 in tumor progression and therapy resistance. Toxicology 2003; 193: 91-109.
14. Huang J, Dynan WS. Reconstitution of the mammalian DNA double-strand break end-joining reveals a requirement for an Mre11/Rad50/NBS1-containing fraction. Nucleic Acids Res 2002; 30: 667-674.
15. Freit P, Canitrot Y, Muller C, et al. Cross-resistance to ionizing radiation in a murine leukemic cell line resistant cis-dichlorodiammineplatinum(II): role of Ku autoantigen. Mol Pharmacol 1999; 56: 141-146.
16. Myint WK, Ng C, Raaphorst GP. Examining the non-homologous repair process following cisplatin and radiation treatments. Int J Radiat Biol 2002; 78: 417-424.
17. Britten RA, Kuny S, Perdue S. Modification of non-conservative double-strand break (DSB) rejoining activity after the induction of cisplatin resistance in human tumour cells. Br J Cancer 1999; 79: 843-849.
18. Omori S, Takiguchi Y, Suda A, et al. Suppression of a DNA double-strand break repair gene, Ku70, increases radio- and chemosensitivity in a human lung carcinoma cell line. DNA Repair 2002; 29: 299-310.
19. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 1998; 58: 1120-1123.
20. Aloyz R, Xu ZY, Bello V, et al. Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res 2002; 62: 5457-5462.
21. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000; 275: 23 899-23 903.
22. Raderschall E, Stout K, Freier S, Suckow V, Schweiger S, Haaf T. Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res 2002; 62: 219-225.
23. Tijsterman M, Plasterk RH. Dicers at RISC; the mechanism of RNAi. Cell 2004; 117: 1-3.
24. Dorsett Y, Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov 2004; 3: 318-329.
25. Miyagishi M, Hayashi M, Taira K. Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev 2003; 13: 1-7.
26. Yokota T, Miyagishi M, Hino T, et al. siRNA-based inhibition specific for mutant SOD1 with single nucleotide alternation in familial ALS, compared with ribozyme and DNA enzyme. Biochem Biophys Res Commun 2004; 314: 283-291.
27. Sioud M. Ribozyme- and siRNA-mediated mRNA degradation: a general introduction. Methods Mol Biol 2004; 252: 1-8.
28. Kaneda Y, Nakajima T, Nishikawa T, et al. HVJ (hemagglutinating virus of Japan) envelope vector as a versatile gene delivery system. Mol Ther 2002; 6: 219-226.
29. Oshima K, Shimamura M, Mizuno S, et al. Intrathecal injection of HVJ-E containing HGF gene to cerebrospinal fluid can prevent and ameliorate hearing impairment in rats. FASEB J 2004; 18: 212-214.
30. Itoh Y, Kawamata Y, Harada M, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003; 422: 173-176.
31. Ahn J-D, Morishita R, Kaneda Y, et al. Inhibitory effects of novel AP-1 decoy oligodeoxynucleotides on vascular smooth muscle cell proliferation in vitro and neointimal formation in vivo. Circ Res 2002; 90: 1325-1332.
32. Collis SJ, Swartz MJ, Nelson WG, DeWeese TL. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res 2003; 63: 1550-1554.
33. Belenkov AL, Paiement J-P, Panasci LC, Monia BP, Chow TYK. An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059 malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents. Cancer Res 2002; 62: 5888-5896.
34. Peng Y, Zhang Q, Nagasawa H, Okayasu R, Liber HL, Bedford JS. Silencing expression of the catalytic subunit of DNA-dependent protein kinase by small interfering RNA sensitizes human cells for radiation-induced chromosome damage, cell killing, and mutation. Cancer Res 2002; 62: 6400-6404.
35. Jensen R, Glazer P. Cell-interdependent cisplatin killing by Ku/DNA-dependent protein kinase signaling transduced through gap junctions. Proc Natl Acad Sci U S A 2004; 101: 6134-6139.
36. Durant S, Karran P. Vanillins - a novel family of DNA-PK inhibitors. Nucleic Acids Res 2003; 31: 5501-5512.
37. Ohnishi T, Taki T, Hiraga S, Arita N, Morita T. In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the Rad51 gene. Biochem Biophys Res Commun 1998; 245: 319-324.
38. Liu CM, Liu DP, Dong WJ, Liang CC. Retrovirus vector-mediated stable gene silencing in human cell. Biochem Biophys Res Commun 2004; 313: 716-720.
39. Abbas-Terki T, Blanco-Bose W, Deglon N, Pralong W, Aebischer P. Lentiviral-mediated RNA interference. Hum Gene Ther 2002; 13: 2197-2201.
40. Russell JS, Brady K, Burgan WE, et al. Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 2003; 63: 7377-7383.
41. Hansen LT, Lundin C, Spang-Thomsen M, Peterson LN, Helleday T. The role of Rad51 in etoposide (VP16) resistance in small cell lung cancer. Int J Cancer 2003; 105: 472-479.
42. Lim DS, Hasty P. A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. Mol Cell Biol 1996; 16: 7133-7143.
43. Miyata T, Yamamoto S, Sakamoto K, Morishita R, Kaneda Y. Novel immunotherapy for peritoneal dissemination of murine colon cancer with macrophage inflammatory protein-1β mediated by a tumor-specific vector, HVJ-cationic liposomes. Cancer Gene Ther 2001; 8: 852-860.